Compounds targeting proteins, compositions, methods, and uses thereof

Patent metadata

Field	Value
Publication number	US-11345714-B2
Application number	US-202117146479-A
Country	US
Kind code	B2
Filing date	Jan 11, 2021
Priority date	Dec 21, 2016
Publication date	May 31, 2022
Grant date	May 31, 2022

Abstract

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

and pharmaceutically acceptable salts and solvates thereof.

2. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

3. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

5. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

6. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

7. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

8. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

9. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

11. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

12. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

13. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

14. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

15. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

16. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

17. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

18. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

19. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

20. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

21. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

22. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

23. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

24. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

25. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

26. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

27. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

28. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

29. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

30. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt or solvate thereof.

31. The compound of claim 1 , wherein the compound is

Assignees

• Biotheryx Inc

Inventors

• Chan Kyle W H
• Erdman Paul E
• Fung Leah M
• Mercurio Frank
• Sullivan Robert W
• Torres Eduardo

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title